Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Reliability of pathogen control in direct potable reuse: Performance evaluation and QMRA of a full-scale 1 MGD advanced treatment train.

Pecson BM, Triolo SC, Olivieri S, Chen EC, Pisarenko AN, Yang CC, Olivieri A, Haas CN, Trussell RS, Trussell RR.

Water Res. 2017 Oct 1;122:258-268. doi: 10.1016/j.watres.2017.06.014. Epub 2017 Jun 6.

2.

Chemotaxis Increases the Residence Time of Bacteria in Granular Media Containing Distributed Contaminant Sources.

Adadevoh JS, Triolo S, Ramsburg CA, Ford RM.

Environ Sci Technol. 2016 Jan 5;50(1):181-7. doi: 10.1021/acs.est.5b03956. Epub 2015 Dec 21.

PMID:
26605857
3.

Anesthetic techniques and cancer recurrence after surgery.

Fodale V, D'Arrigo MG, Triolo S, Mondello S, La Torre D.

ScientificWorldJournal. 2014 Feb 6;2014:328513. doi: 10.1155/2014/328513. eCollection 2014. Review.

4.

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M.

Haematologica. 2001 Apr;86(4):399-403.

5.

Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.

Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, Grasso M, Liberati M, Lotesoriere C, Marcenò R, Marmont F, Musto P, Petrucci MT, Spriano M, Pileri A, Boccadoro M.

Haematologica. 2000 May;85(5):508-13.

6.

Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.

Boccadoro M, Omedé P, Dominietto A, Palumbo A, Bringhen S, Giaretta F, Ortolano B, Triolo S, Pileri A.

Bone Marrow Transplant. 2000 Jan;25(1):25-9.

7.

An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.

Boccadoro M, Tarella C, Palumbo A, Argentino C, Triolo S, Dominietto A, Callea V, Lauta VM, Molica S, Musto P, Marmont F, Gianni AM, Pileri A.

Haematologica. 1999 Oct;84(10):905-10.

8.

Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.

Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omedè P, Tarella C, Pileri A, Boccadoro M.

Blood. 1999 Aug 15;94(4):1248-53.

9.

Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses.

Omedè P, Tarella C, Palumbo A, Argentino C, Caracciolo D, Corradini P, Dominietto A, Giaretta F, Ravaglia R, Triolo R, Triolo S, Pileri A, Boccadoro M.

Br J Haematol. 1997 Dec;99(3):685-91.

PMID:
9401085
10.

Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies.

Triolo R, Omedè P, Giaretta F, Ravaglia R, Battaglio S, Palumbo A, Dominietto A, Argentino C, Triolo S, Pileri A, Boccadoro M.

Eur J Histochem. 1997;41 Suppl 2:57-8. No abstract available.

PMID:
9859783
11.

Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients.

Palumbo A, Pileri A, Triolo S, Omedè P, Bruno B, Ciravegna G, Galliano M, Frieri R, Boccadoro M.

Bone Marrow Transplant. 1997 Jan;19(1):23-9.

12.

Metabolic markers for the early diagnosis of postmenopausal osteoporosis.

Isaia G, Mussetta M, Di Stefano M, Sciolla A, Triolo S, Molinatti GM.

J Endocrinol Invest. 1994 Nov;17(10):771-4.

PMID:
7699209
13.

Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma.

Palumbo A, Boccadoro M, Bruno B, Triolo S, Pileri A.

Haematologica. 1994 Nov-Dec;79(6):513-8.

14.

Recombinant interferon-gamma in a patient with multiple myeloma.

Palumbo A, Bruno B, Triolo S, Boccadoro M, Pileri A.

Eur J Cancer. 1994;30A(11):1731. No abstract available.

PMID:
7833155

Supplemental Content

Loading ...
Support Center